P. Petrinelli
Sapienza University of Rome
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by P. Petrinelli.
Human Genetics | 1985
Massimo Fiorilli; A. Antonelli; Giandomenico Russo; Marco Crescenzi; Maurizio Carbonari; P. Petrinelli
SummaryIn the present study we examined cells from several patients clinically diagnosed as having ataxia-telangiectasia (AT), for the capacity of their cells to inhibit DNA synthesis following exposure to gamma irradiation, and for the rate of spontaneous or blcomycin-induced chromosomal aberrations. Cells from two patients showed normal inhibition of DNA synthesis and levels of induced chromosomal aberrations intermediate between normal and AT cells. These two patients had only minimal immunologic impairment. These findings appear to define one distinct subset of AT.
Human Genetics | 1984
P. Petrinelli; A. Antonelli; L. Marcucci; Bruno Dallapiccola
SummaryCytogenetic investigations performed on lymphocytes from a 29-year-old woman with no severe anomalies, allowed us to recognize a mild form of Roberts syndrome. The propositas metaphases showed a consistent centromere splitting, especially affecting chromosomes 16, 19, 21, and 22. This centromere separation sequence seems to be unique to Roberts syndrome cells. The experiments also showed that no diffusible factor, involved in the mechanism of sister chromatid pairing-disjunction, exists.
Cancer Genetics and Cytogenetics | 1996
Raffaella Elli; Luciana Chessa; A. Antonelli; P. Petrinelli; R. Ambra; L. Marcucci
DNA topoisomerase II is involved in DNA topologic changes through the formation of a cleavable complex. This is stabilized by the antitumor drug VP16, which results in DNA breakage, aberrant recombination, and cell death. In this work, we compare the chromosomal damage induced by VP16 with that induced by bleomycin (BLM) in lymphoblasts from patients affected by the chromosome breakage syndromes ataxia telangiectasia (AT), xeroderma pigmentosum (XP), and Bloom syndrome (BS), and by the progeroid syndromes Werner (WS) and Cockayne (CS). Patients affected by AT, XP, BS, and WS have a greatly enhanced risk of developing cancer. The results show that AF and WS cells are hypersensitive to VP16, as revealed in the higher proportion of metaphases showing exchange figures and more than two breaks. All lines except AT and one CS line showed normal sensitivity to BLM. Our data on the sensitivity to VP16 of all these mutant cells underline the fact that VP16 damage is amplified only in cells that have abnormal illegitimate recombination (i.e., AT and WS).
Environmental and Molecular Mutagenesis | 1998
I. D'Agnano; A. Antonelli; B. Bucci; L. Marcucci; P. Petrinelli; R. Ambra; G. Zupi; Raffaella Elli
Poly(ADP‐ribose) polymerase (PARP) is a DNA‐binding protein involved in cellular response to various genotoxic agents. To understand the role of PARP in the mechanisms which lead from specific DNA damage to cell death, we studied the effects of PARP inhibition in human lymphoblasts damaged with bleomycin (BLM) and VP16. These agents can induce DNA breakage but through different mechanisms, enabling the study of the different effects of PARP in inducing apoptosis in damaged cells. We demonstrate that in lymphoblasts VP16 treatment induces apoptosis to a greater extent than BLM treatment, and that PARP inhibition reduces VP16‐induced apoptosis whereas it has no effect on BLM‐induced apoptosis. After VP16 treatment with PARP inhibition, a reduction in the depletion of the proliferative compartment and a G2/M phase arrest are observed. Therefore, the increase in cell viability and the reduction in chromosome damage may both be the result of a prolonged DNA repair time. Hence, PARP appears to play a significant role in VP16‐induced apoptosis and not in BLM‐induced apoptosis. Since apoptosis is important in tumor treatment these findings might be useful when considering the combined employment of PARP inhibition with antineoplastic drugs. Environ. Mol. Mutagen. 32:56–63, 1998.
European Journal of Pediatrics | 1993
Vincenzo Leuzzi; Raffaella Elli; A. Antonelli; Luciana Chessa; F. Cardona; L. Marcucci; P. Petrinelli
The clinical diagnosis of ataxia-telangiectasia (AT) is difficult before the age of 4 years. We report clinical and cytogenetic data on three early-onset, early-diagnosed AT patients at the age of 12, 18 and 22 months, respectively. Postural instability of the trunk, characterized by motor impersistence, was the earliest neurological sign detected as early as 1 year of life. Dystonic movements and postures of arms and trunk and a subtle disorder of eye movement (blinking before gaze changing, increased latency and dysmetry of saccades) were observed during the 2nd year of life. All patients exhibited an unusual temper tantrum. We also observed an increased bleomycin-induced chromosomal instability in patients cells in the early stages of the disease before all the clinical hallmarks were apparent. Our data suggest that detection of clinical indications, leading to early laboratory confirmation of AT, can reduce the age at diagnosis.
Cancer Genetics and Cytogenetics | 2001
P. Petrinelli; Raffaella Elli; L. Marcucci; Elisabetta Tabolacci; Concetta Barbieri; A. Antonelli
T-cell tumors in ataxia telangiectasia (AT), such as T-PLL/T-CLL, are first preceded by the development of a large clone of T-lymphocytes, characterized by chromosomal rearrangements, which usually involve specific regions such as the 14q11 region. Malignancy develops years later, after additional chromosomal changes resulting from the genomic instability consequent to ATM disruption and to the activation of the TCL1 oncogene. Here we report the results of a cytogenetic follow-up of an AT patient (AT94-1), still without signs of hematological abnormalities, bearing a T-lymphocyte clone characterized by the t(14;14)(q11;q32) rearrangement and having TCL1 expression. We demonstrated that in clonal cells TCL1 expression correlates with increasing genomic instability and in time this mainly induces chromosomal rearrangements and telomeric associations (tas). Chromosome 21 is not randomly involved; in particular, an i(21q) indicates that it is a subclone prone to additional genetic changes and could represent an early chromosomal rearrangement involved in tumorigenesis. With regard to the increase in tas, we observed that: (i) it is inversely correlated with the proliferative ability of AT94-1 lymphocytes in PHA-stimulated short-term cultures (cell aging in vitro); (ii) this increase is not due to changes either in cell radiosensitivity (measured as bleomycin (BML)-sensitivity) or due to an illegitimate recombination (measured as adriamycin-sensitivity), which may not be sufficient for tumor development.
British Journal of Cancer | 2003
Chiara Gabellini; Amanda Antonelli; P. Petrinelli; Annamaria Biroccio; L. Marcucci; Giovanni Nigro; Giandomenico Russo; Gabriella Zupi; Raffaella Elli
Individuals affected by ataxia telangiectasia (AT) have a marked susceptibility to cancer. Ataxia telangiectasia cells, in addition to defects in cell cycle checkpoints, show dysfunction of apoptosis and of telomeres, which are both thought to have a role in the progression of malignancy. In 1–5% of patients with AT, clonal expansion of T lymphocytes carrying t(14;14) chromosomal translocation, deregulating TCL1 gene(s), has been described. While it is known that these cells can progress with time to a frank leukaemia, the molecular pathway leading to tumorigenesis has not yet been fully investigated. In this study, we compared AT clonal cells, representing 88% of the entire T lymphocytes (AT94-1) and expressing TCL1 oncogene (ATM− TCL1+), cell cycle progression to T lymphocytes of AT patients without TCL1 expression (ATM− TCL1−) by analysing their spontaneous apoptosis rate, spontaneous telomerase activity and telomere instability. We show that in ATM− TCL1+ lymphocytes, apoptosis rate and cell cycle progression are restored back to a rate comparable with that observed in normal lymphocytes while telomere dysfunction is maintained.
Mutation Research-dna Repair | 1991
A. Antonelli; Raffaella Elli; L. Marcucci; Roberto Bosi; Donatella Kobal; P. Petrinelli
Ataxia telangiectasia (AT) cells are known to be hypersensitive to ionizing radiations and to drugs such as bleomycin and epipodophyllotoxin VP16, a topoisomerase II poison. Both of these produce DNA double-strand breaks even if through different mechanisms. In this work we analyzed the sensitivity to bleomycin and to epipodophyllotoxin of AT cells after transfection with pR plasmid. This plasmid, interacting with bacterial SOS repair pathways, expresses itself in mammalian cells conferring cell resistance to the SOS inducers UV and 4NQO and cell sensitivity to different drugs such as bleomycin. This effect is presumably due to the interaction of pR products with double-strand breaks. Our findings indicate that pR plasmid, in both AT lines tested (AT5BIVA fibroblasts and ATL6 lymphoblasts), expresses itself (increasing UV protection) and amplifies the already enhanced AT cell sensitivity to both bleomycin and VP16.
The American Journal of the Medical Sciences | 1998
Antonio Camagna; Pietro Del Duca; P. Petrinelli; Lola G. Borelli; Loreta Ciancio; Lorena Cipollone; Gloria Misasi; Maria R. Manfredi; S. Dionisi; Carlo De Martinis
ABSTRACT A marked discrepancy betweenmild and late clinical features and a nearly completeabsence of erythrocyte uroporphyrinogendecarboxylase activity (Ery-UROD activity) wasobserved in a case of inherited porphyria cutaneatarda. The entity and time of appearanceof clinical features, the onset of clinical symptomsafter exposure to contributing factors, theeffectiveness of phlebotomies and heterozygosityof the mother alone for uroporphyrinogendecarboxylase (UROD) deficiency were typicalfor familial porphyria cutanea tarda (F-PCT),whereas the extremely low UROD activity waspeculiar to hepatoerythropoietic porphyria(HEP). These observations indicate that: 1) EryURODactivity may not always be useful to discriminatebetween F-PCT and HEP; 2) EryURODactivity does not always correlate withclinical symptoms; 3) in inherited UROD deficiency,the genetic defect may be heterogeneous.Finally, the observed discrepancy may provideadditional evidence for the existence of tissuespecificisozymes.
Annals of the New York Academy of Sciences | 1992
A. Antonelli; P. Petrinelli; L. Marcucci; D. Billi; F. Cardona; V. Leuzzi; Raffaella Elli
Cockayne syndrome (CS) is an autosomal recessive disorder characterized by progeria, dwarfism, psychomotor retardation, and photosensitive dermatitis. CS cells are hypersensitive to ultraviolet light,’** 4NQ0, and N-Aco-AAF,~ whereas abnormal gamma ray sensitivity was reported only in some CS line^.^,^ In the present work, we studied cells from a 17-year-old patient with typical CS by: (1) measuring the RNA synthesis rate after UV irradiation in primary fibroblasts; ( 2 ) evaluating the chromosome damage induced in lymphoblastoid cells by BLM (a radiomimetic antibiotic) and VP16 (a DNA topoisomerase I1 inhibitor); these both induce DNA strand breaks through different mechanisms.